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Background: Coronary artery disease (CAD) is a major cause of death and disability worldwide. Depression has
complex bidirectional adverse associations with CAD, although the mechanisms mediating these relationships remain
unclear. Compared to European Americans, African Americans (AAs) have higher rates of morbidity and mortality from
CAD. Although depression is common in AAs, its role in the development and features of CAD in this group has not
been well examined. This project hypothesizes that the relationships between depression and CAD can be explained
by common physiological pathways and gene-environment interactions. Thus, the primary aims of this ongoing
project are to: a) determine the prevalence of CAD and depression phenotypes in a population-based sample of
community-dwelling older AAs; b) examine the relationships between CAD and depression phenotypes in this
population; and c) evaluate genetic variants from serotoninP and inflammatory pathways to discover potential
gene-depression interactions that contribute significantly to the presence of CAD in AAs.
Methods/design: The St. Louis African American Health (AAH) cohort is a population-based panel study of
community-dwelling AAs born in 1936–1950 (inclusive) who have been followed from 2000/2001 through 2010.
The AAH-Heart study group is a subset of AAH participants recruited in 2009–11 to examine the inter-relationships
between depression and CAD in this population. State-of-the-art CAD phenotyping is based on cardiovascular
characterizations (coronary artery calcium, carotid intima-media thickness, cardiac structure and function, and
autonomic function). Depression phenotyping is based on standardized questionnaires and detailed interviews.
Single nucleotide polymorphisms of selected genes in inflammatory and serotonin-signaling pathways are being
examined to provide information for investigating potential gene-depression interactions as modifiers of CAD
traits. Information from the parent AAH study is being used to provide population-based prevalence estimates.
Inflammatory and other biomarkers provide information about potential pathways.
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Discussion: This population-based investigation will provide valuable information on the prevalence of both
depression and CAD phenotypes in this population. The study will examine interactions between depression and
genetic variants as modulators of CAD, with the intent of detecting mechanistic pathways linking these diseases to
identify potential therapeutic targets. Analytic results will be reported as they become available.
Keywords: Coronary artery disease, Depression, Genetic analyses, African Americans, Inflammatory biomarkers,
Inflammatory pathway, Serotonin-signaling pathway, Heart rate variability, Built environment, Bayesian analysisBackground
Coronary artery disease (CAD) is the leading cause of
cardiovascular morbidity and mortality and one of the
most prevalent chronic diseases in the industrialized world
and in most developing countries [1]. Over 82 million
Americans have at least one type of cardiovascular disease
[2]. In 2008, CAD was responsible for one out of every six
deaths in the Unites States, and each year 1.26 million
Americans suffer a new or recurrent myocardial infarction
[2]. Cardiac events are more prevalent in depressed patients
with CAD, and patients with CAD have increased burden
of depressive conditions.
Depression is a risk factor for incident CAD and for
cardiac-related morbidity and mortality [3-17]. Depression
is also highly prevalent in patients with CAD, At any time
point, about 20% of patients with CAD are experiencing an
episode of major depression, and a comparable proportion
have minor depression; [18-23]. Studies have found that a
history of major depression, [3,4] depression symptoms,
[5-12] clinical depression, [4,13-16] and an increase in
depression symptoms over time [16,17] predict incidence
of heart disease and death from cardiac causes. Depression
is not only a risk factor for incident CAD, but also for
cardiac mortality and morbidity in patients who have
established heart disease. Depression doubles the risk for
cardiac events, including cardiac mortality, in the 12 months
following initial diagnostic coronary catheterization and
angiography [7,24]. Depression is also is a risk factor for
mortality and cardiac events in patients undergoing coron-
ary artery bypass graft surgery, [7,25,26] and following an
acute coronary syndrome [27-41].
The INTERHEART study, comprised of 15,542 cases
and 14,820 controls from 52 countries representing
diverse world populations, identified 9 modifiable risk
factors (smoking, diabetes, hypertension, abdominal
obesity, fruits/vegetable intake, exercise, alcohol consump-
tion, ApoB/ApoA1 ratio, and a psychosocial index) that
account for 90% of the population attributable risk for
myocardial infarction. The psychosocial index (a composite
score reflective of depression, locus of control, perceived
stress, and life events) was responsible for 32.5% of the
population attributable risk for CAD, which was greater
than the risk associated with each of hypertension, diabetes,
abdominal obesity, fruit/vegetable intake, and alcoholconsumption [42,43]. While depression and CAD may
be two common independent disorders, it is possible
that common pathophysiological mechanisms underpin
both diseases.
However, the precise molecular and genetic mechanisms
that may underlie both diseases remain largely unknown.
Plausible pathways through which depression may increase
the risk of cardiac morbidity and mortality include interac-
tions between genetic variants and depressive phenotype
(representing the environment) [44-46]. There is extensive
evidence that mood disorders are heritable [47,48]. For ex-
ample, heritability has been estimated on the order of 40%
for unipolar depression [49]. The strongest familial risk is
found in patients with recurrent major depression [50,51].
There is also evidence that cardiac risk factors and ische-
mic heart disease are heritable [52-55]. Recent studies have
considered whether shared genetic factors help explain the
relationship between depression and CAD. A variance
component analysis of 2,731 male-male twin pairs from
the Vietnam Era Twin Registry (mean age 42 ± 3 years)
showed that shared genetic risk factors may underlie this
relationship, as significant genetic correlations between
depression and hypertension (r = .19) and between de-
pression and CAD (r = .42) were found [44]. Importantly,
statistical models have shown that CAD shares at least
as much genetic variance with depression as it does with
hypertension [56].
Inflammatory and serotonin-signaling pathways have
been identified as risk factors for both CAD and depres-
sion. There is ample evidence to support a critical role for
proinflammatory cytokines in the development of CAD,
and inflammatory biomarkers have been associated with a
variety of CAD-related traits [57,58]. The most studied of
these biomarkers is the acute phase reactant C-reactive
protein (CRP), which has been shown to be independently
associated with the presence of carotid plaque [59] and
increased carotid intima-media thickness; [60] it is also
predictive of future CAD events [61-66]. Increases in
inflammatory biomarkers have also been associated with
depression, [67,68] and inflammation has been postulated
to mediate the association between depression and CAD
[69]. Serotonin, which is secreted by activated platelets,
promotes thrombogenesis, mitogenesis, and proliferation of
smooth muscle cells and has been shown to be associated
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adjustment for conventional risk factors [70]. Furthermore,
diminished heart rate variability, a biomarker representing
disordered autonomic function associated with cardio-
vascular mortality, has been identified in depression and
anxiety. Treatment with serotonin-reuptake inhibitors
may normalize heart rate variability in these patients
[71]. Since inflammation and serotonin signaling pathways
have been identified as risk factors for CAD events and
associated with depression, it has been postulated that
genetic variants in these pathways may mediate the as-
sociation between depression and CAD [72].
African Americans (AAs) have traditionally been an
understudied group in all aspects of biomedical and be-
havioral research; this is particularly true with depression,
and more so in studies investigating the genetic underpin-
nings of depression. Nationally, AAs have higher rates
of morbidity and mortality from CAD than European
Americans; [73] notably, rates of death from heart disease
are 1.2 times higher among AAs in the City of St. Louis
compared with the national average [74]. Limited data
suggest that the prevalence of major depressive disorder is
at least as high in AAs as in European Americans [75,76].
Despite its importance, we are unaware of any studies
examining shared biological pathways and genetic expla-
nations for the depression-CAD relationship in AAs.
The St. Louis African American Health (AAH) cohort is
a population-based cohort study of community-dwelling
AAs born in 1936–1950 (inclusive). The AAH-Heart study
group is a subset of AAH participants who were recruited
in 2009–11 to examine the inter-relationships between de-
pression and CAD in this population and examine potential
biological pathways and genetic underpinnings that could
explain the identified relationships. This publication
describes the structure and content of the project. Analytic
results will be reported as they become available.
Methods/design
Objectives
The primary objectives of AAH-Heart are three-fold: First,
to identify the prevalence of CAD and depression in a
population-based sample of community-dwelling AAs aged
59–75 years-old. Second, to examine the relationships be-
tween CAD and depression. Third, to evaluate interactions
between depression and variants in serotonin-signaling
and inflammatory pathway genes (representing gene-
environment interactions) potentially to identify underlying
physiological mechanisms that help explain the identified
relationships between depression and CAD. Phenotypes for
both CAD and depression will be defined using clinically
relevant definitions based on state-of-the-art methods for
characterizing these phenotypes. We will also investigate
multiple biomarkers as potential mediators of previously
identified depression-CAD-gene relationships.Study design
Study population
Study participants were recruited from the parent African
American Health (AAH) project, a well-characterized
cohort of 998 community-dwelling AAs representing
the AA population in two diverse geographic and so-
cioeconomic areas of St. Louis, MO. Participants were
self-declared African American or black, born between
1936 and 1950 (inclusive; aged 49–65 at their baseline
evaluation in 2000–2001), with an initial recruitment
rate of 76%. They were followed through 2010 (9 years),
and wave-to-wave retention was 95% among surviving
participants. AAH recruitment and sampling procedures
have been previously described [77]. The AAH cohort
underwent 7 waves of assessments (3 in-home and 4 by
telephone) that included characterization of important
life course factors (e.g., reported weight; self-reported
physical activity; physical, cognitive, and psychosocial
functioning; comorbid diseases; socioeconomic status;
and health-related quality of life). Importantly, sampling
weights supplied by the contract survey organization
combined with propensity score re-weighting adjustments
for differential involvement in AAH-Heart permit the
AAH-Heart results to represent population-based estimates
of the noninstitutionalized AA population in the original
parent study areas as of the 2000 Census [78].
Enrollment
From 2009–2011, 735 AAH participants, representing the
remaining AAH members available in 2009, were contacted
via mail and/or telephone and asked to participate in the
AAH-Heart study. Of these, 430 (58.1%) were not enrolled
to the AAH-Heart ancillary study for the following rea-
sons: declined participation (n = 152), failure to contact
(e.g., multiple attempts, disconnected or wrong telephone
numbers; n = 246), relocation outside the St. Louis metro-
politan area, institutionalized, or incarcerated (n = 26), or
death since 2009 (6). A total of 305 (41.5%) of the potential
735 AAH participants were enrolled in the AAH-Heart
study (Figure 1).
Ethical approval
The study is a joint effort of three academic institutions.
The protocol was approved in full by the ethics committee
at Washington University School of Medicine, and parts
related to involvement of their institution were approved
by the ethics committees of Saint Louis and Indiana
Universities. Written informed consent was obtained
from all AAH-Heart participants.
Data collection
Data for AAH-Heart were collected from June 2009 to
November 2011. All tests, questionnaires, and interviews
were administered by trained personnel using standardized
African American Health-Heart Potential Study Participants = 735
AAH-Heart consented and enrolled = 305 (41.5%)
Participation Declined = 152 (35.3%)
Failure to Contact 
(multiple attempts, disconnected/incorrect 
telephone numbers, unsuccessful
tracing) = 246 (57.2%)
Relocated outside St. Louis 
metropolitan area, institutionalized
or incarcerated = 26 (6.0%) 
Death = 6 (1.4%)
Excluded = 430 (58.5%)
Figure 1 Flow chart for enrollment into the African American Health-Heart (AAH-Heart) study.
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investigators. Table 1 provides an overview of the variables
and measurement details.
Cardiovascular risks and characteristics
A Medical History. Participants’ general health status
was characterized using the Charlton Comorbidity
Index [79,80]. This instrument collects data
regarding cardiovascular, neurologic/cerebrovascular,
connective tissue, gastrointestinal, malignant, and
pulmonary diseases. Data on medications and other
health-related supplements were also collected by
review of a self-reported medication list and/or
examination of medication bottles.
B Cardiovascular health and behavior questionnaires.
Six questions were obtained to determine
consumption of certain fruit and vegetables [81].
Participants were also questioned regarding current
and past tobacco use. The nine-item International
Physical Activity Questionnaire-Short Form was
administered to characterize the duration and
intensity of physical activity [82].
C Anthropometric and hemodynamic measurements.
Participants’ weight, height, and waist/hip
circumferences were measured. Three blood
pressures were obtained in each arm after five
minutes of rest in the seated position and averaged.
The heart rate was obtained from a 12-lead
electrocardiogram.
D Ankle-Brachial Index (ABI). ABI was obtained by
measuring the blood pressures in the brachial
arteries and in the posterior tibial and dorsalis pedis
arteries using a hand-held Doppler probe using
standard techniques.E Six-minute walk distance test. For this self-paced,
submaximal exercise test, individuals were asked to
walk without physical assistance as fast as they could
during a six-minute timed period [83].
F Coronary artery calcification. Participants were
examined using a 64-slice dual-source multi-detector
computerized tomography (MDCT) scanner
(Somatom Sensation 64, Siemens, Forchheim,
Germany) for characterization of coronary, carotid,
and thoracic aorta calcification. Scan parameters
included 24×1.2 mm collimation, 1.5 mm slice
thickness, 0.37 sec rotation time, spiral mode,
120 kVp, 80 mAs. Cardiac-pulsing imaging reduced
radiation exposure and cardiac motion. The scan
was acquired during a single breath-hold at
suspended end-expiration (~5-15 sec duration).
MDCT images were transferred to a workstation
equipped for analysis. Intra- and inter-reader
intraclass correlation coefficients for coronary
calcium scores/volumes in our laboratory were ≥0.82
and ≥0.97, respectively.
G Echocardiography. M-Mode, two-dimensional, and
Doppler echocardiographic measurements were
performed for assessment of left ventricular (LV)
structure and function. LV ejection fraction was
calculated by the two-dimensional-derived method
of discs. LV mass (LVM) was determined by the
M-mode-derived cubed method and indexed to
height2.7 (LVM/Ht2.7). The presence of left
ventricular hypertrophy is defined as an LVM/Ht2.7
greater than two standard deviations above the mean
(i.e. >51 g/m2.7 for men, >49.5 g/m2.7 for women) [84].
LV diastolic function was characterized as follows:
1) pulse-wave Doppler-derived transmitral indices
recorded from the four-chamber view at the mitral
Table 1 Variables and instruments
Variables Instruments
Cardiovascular
Coronary, carotid, and thoracic aorta calcium scores 64-slice dual-source MDCT scanner
CIMT and carotid plaque burden Bilateral carotid artery ultrasound imaging (mm)
ECG-derived - time domain analysis, frequency domain analysis,
heart rate turbulence
24-hour Holter monitor
LV structure, LV systolic/diastolic function, valve function Echocardiography
Heart rate Echocardiogram
Aortic compliance- pulse wave analysis, pulse wave velocity SphygmoCor (AtCor Medical, Sydney, Australia)
Cardiovascular history Charleston comorbidity Index (17 items)
Blood pressure 3 times right and left arms
Ankle brachial index Pocket fetal doppler Sonoline B
(Clinical Guard, Atlanta, GA)
6-minute walk test Marked distance totaled
Emotional status
DSM IV diagnosis: current and lifetime major unipolar depression,
generalized anxiety and panic disorder
DISH (38 items)
Hamilton rating scale: severity of current depression
Psychiatric history
Screen for all exclusionary psychiatric conditions
Stressful/traumatic life events LEC (1–15 events)
Depression CES-D (11 items;≥9 points indicates clinically-relevant number
of depressive symptoms)
Current clinical covariates
Fruit and vegetable consumption CDC questionnaire (6 items)
Medication use Self-report
Tobacco and alcohol use Self-report
Anthropometrics- height, weight, waist/hip Trained research members
Physical activity IPAQ-short (9 items)
Laboratory & biomarker assays
BMP, fasting glucose, fasting lipid profile, and HgbA1C Fasting blood draw
CRP, TNF-α, TNFR1, TNFR2, IL-6, TGF-β, VCAM, ICAM, MMP-9 Panomics multiplex immunoassay
(Affymetrix, Santa Clara, CA)
Built environment
Neighborhood of residence location Questionnaire re: location; geographic information system analyses
and in-person assessments as part of parent AAH study (2010)
Abbreviations: BMP basic metabolic panel, CDC centers for disease control and prevention, CES-D center for epidemiologic studies depression scale, CIMT carotid
intima-media thickness, CRP c-reactive protein, DISH depression interview and structured hamilton, DSM IV diagnostic and statistical manual of mental disorders
fourth edition, EKG electrocardiogram, HbgA1C hemoglobin A1C, ICAM intercellular adhesion molecule, IL-6 Interleukin-6, IPAQ-Short international physical activity
questionnaires-short form, LEC life events checklist, LV left ventricle, MDCT multi-detector computerized tomography, MMP-9 matrix metalloproteinase-9, TGF-β
transforming growth factor-beta, TNF-α, tumor necrosis factor-alpha, TNFR1 tumor necrosis factor receptor 1, TNFR2 denotes tumor necrosis factor receptor 2,
VCAM vascular cell adhesion molecule.
Bruchas et al. BMC Cardiovascular Disorders 2013, 13:66 Page 5 of 12
http://www.biomedcentral.com/1471-2261/13/66valve leaflet tips, including the early diastolic
(E-wave) and atrial (A-wave) velocities, E/A
velocity ratio, E-wave deceleration time, and the
isovolumic relaxation time; [85] 2) tissue Doppler
imaging-derived early diastolic mitral annular
velocity (E’) obtained at the septal and lateral
mitral annulus from the apical four-chamber view,and averaged [85-88]. Measurements were
reported as the average of three consecutive
cardiac cycles, interpreted by an experience
sonographer. The intraclass correlation coefficients
for echocardiographic indices measured at our
laboratory range from 0.75-0.88 for LV structure
(i.e., LVM, LV end-diastolic and end-systolic
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Doppler imaging-derived indices of LV diastolic
function (i.e., E’ at the septal and lateral annulus).
H Carotid artery ultrasound for measurement of
carotid intima-media thickness (CIMT). Bilateral
carotid artery ultrasound imaging was performed
using a 9-MHz linear array transducer of the
extracranial carotid artery at the common carotid,
approximately 1 cm proximal to the carotid
bifurcation, using methods previously described
[89]. Atherosclerotic plaque was defined as a focal
intima-media thickness >1.5 mm or focal wall
thickening that protruded into the lumen >0.5 mm
or >50% of the surrounding CIMT.
I 24-hour Holter monitor. Holter monitor recordings
were analyzed using a CardioScan PC-based Holter
analyzer, using standard research Holter analysis
techniques to create an annotated beat-to-beat
interbeat intervals file. Interbeat interval files were
transferred to a Sun 450 computer for detailed heart
rate variability (HRV) analysis using validated
research software. Abnormal HRV, either markedly
decreased or markedly erratic beat-to-beat changes
in heart rate, is a marker for abnormal cardiac
autonomic function [90]. HRV parameters included
time domain measures, which are moment statistics
of the amount of HRV on different scales and reflect
the amount of autonomic modulation of heart rate.
Detailed information on cardiac autonomic function
at different underlying frequencies was obtained
using frequency domain analysis of HRV. Non-linear
HRV measures that assess the underlying pattern
(totally random at one extreme and totally
correlated at the other) were also calculated, as was
heart rate turbulence (a measure of autonomic
function derived from the heart rate response to
ventricular premature beats, apparently reflecting
baroreflex function [91-93]). Among predominantly
white community-dwelling older adults in the
Cardiovascular Health Study (CHS), both more
abnormal non-linear HRV measures and abnormal
heart rate turbulence have been associated with a
high risk for cardiovascular mortality independent of
traditional risk factors [94]. Also in CHS, depression
has been associated with both more mortality and
with non-linear HRV [95].
J Characterization of vascular compliance. Central
aortic compliance was characterized by
measurement of the pulse wave velocity (PWV) and
augmentation index using the SphygmoCor™ system
(AtCor, Sydney, Australia) equipped with a single
high-fidelity applanation tonometer probe. For the
PWV, pressures were recorded from the carotid
then femoral arteries; the transit time was calculatedby registration with a simultaneously recorded
electrocardiogram, using methods previously
described [96,97].
Depression and psychosocial history
A Depression Interview: A structured interview, the
Depression Interview and Structured Hamilton
(DISH), was used to diagnose current and lifetime
major unipolar depression according to Diagnostic
and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) criteria; the presence and severity
of current depression was determined from an
embedded Hamilton Rating Scale for Depression,
17-item (HAM-D-17) [98]. The DISH also identifies
depression subtypes (e.g., melancholic or atypical
depression) and comorbid anxiety disorders,
including generalized anxiety and panic disorder.
Family history for psychiatric disorders was
identified, as well as psychiatric conditions which are
exclusions for this study (e.g., bipolar disorder,
schizophrenia).
B Depression Self Report Inventory. The 11-item
Center for Epidemiologic Studies Depression (CES-
D) Scale was administered to assess the presence
and severity of depressive symptoms. A score of ≥9
was used to define clinically significant depressive
symptoms [99].
C The Life Events Checklist captured recent and past
exposures to stressful life events [100].
Built environment
Each participant provided a detailed history of moves
by providing the dates (month/year) and location
(street number and name) of residences occupied since
2000. Additional questions probed reasons for reloca-
tions. This information will be used to determine the
effects of the built environment and/or neighborhood
conditions (such as nearby restaurants, grocery stores,
green space, and yard and sidewalk quality) on cardiovas-
cular and emotional health using geographic information
system methods plus observational data from the parent
study [78,101,102].
Laboratory assays
Blood was obtained by venipuncture at the time of
examination. A basic metabolic profile (glucose, calcium,
sodium, potassium, chloride, bicarbonate, blood urea
nitrogen, and creatinine), lipid profile (low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol,
triglyceride, and total cholesterol), and HgbA1C were
obtained after an overnight fast on the day of enrollment.
After blood extraction and processing, serum and plasma
were stored in 1 mL aliquots in O-ring tubes at -80°C
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inflammatory biomarkers. Inflammatory biomarkers
included CRP, tumor necrosis factor-alpha (TNF-α), tumor
necrosis factor-receptor 1 (TNFR1), tumor necrosis factor
receptor 2 (TNFR2), interleukin-6 (IL-6), transforming
growth factor-beta (TGF-β), vascular cell adhesion molecule
(VCAM), intercellular adhesion molecule (ICAM), and
matrix metalloproteinase-9 (MMP-9), which were assayed
from serum using the Panomics multiplex immunoassay
magnetic bead assay kit (Affymetrix, Santa Clara, CA).
Genetic studies
Whole blood was collected in EDTA-treated vacuum con-
tainers and then frozen at -80°C until DNA extraction using
QIAGEN Autopure LS Large Nucleic Acid Purification
Instrument (Gentra Systems, Minneapolis, MN). Extracted
DNA was stored at −80 C pending genotyping (in process).
Genotyping is being performed using a commercially
available platform at the Washington University Genome
Technology Access Center. Single nucleotide polymor-
phisms are being selected from among inflammatory
and serotonin signaling pathway genes with the goal to
maximize the information content and to test variants
previously implicated in cardiovascular and/or psychiatric
disorders. When referent genetic sequences and/or variant
data are accessed, information from African and African-
American populations will be prioritized.
Statistical analyses
Initial data processing and screening will be carried out
by established procedures for data quality control and
generation of derived variables (e.g., univariate analysis
of individual phenotypes and identifying outliers). Version-
controlled analytic datasets will be made and distributed to
all approved study investigators for downstream analyses.
Latent factor analysis will be performed on panels of
observed cardiovascular findings to extract underlying
patterns of data (i.e., “traits”) more proximally associated
with CAD [103]. The latent factors will first be extracted
from panels of variables representing cardiovascular
attributes, and then again from panels combining both
cardiovascular and depressive characteristics. By comparing
results of analyses using CAD-only versus CAD + depres-
sion latent traits, subtypes of CAD potentially affected by
gene-depression interactions will be identified. Simple
associations between CAD/depression traits and individual
genetic variants will be tested by linear or logistic regres-
sion. A modified generalized linear model accounting for
gene-gene and gene-depression interactions (using both
observed characteristics and extracted latent traits) will be
performed to test modifying effects of depression on CAD
phenotypes. Exploratory Bayesian network analyses will be
performed to obtain an overview of interactions among
the many factors (genetic and non-genetic) important toCAD [104,105]. Additional secondary analyses will explore
whether the association between depression and CAD are
mediated through LV structure/function, [106] autonomic
dysfunction (e.g., HRV), [71] inflammatory biomarkers,
[69] the built environment, [78] and/or health behaviors
(e.g., diet, exercise, tobacco, medication use, etc.) [107]. The
overarching hypothesis is that genes related to the sero-
tonin signaling, inflammatory processes, and/or autonomic
function will help explain the relationships between the
depression phenotype and CAD-related phenotypes.
Discussion
This study was designed to evaluate the contributions
from depression to manifestations of CAD through
common gene-gene and/or gene-environment interactions
via the primary and secondary study objectives described
above. This is an important and innovative study in several
respects. First, the mechanisms contributing to CAD in
AAs are poorly understood. For example, although AAs
experience more morbidity and mortality from CAD than
do European Americans, they have less obstructive CAD
than do European Americans [73]. Second, this study uses
state-of-the-art non-invasive cardiac imaging techniques to
allow exquisite characterization of coronary artery calcium,
CIMT, and left ventricular structure and systolic/diastolic
function to evaluate manifestations of CAD. Likewise, for
the evaluation of depression phenotype, detailed, validated
psychiatric interviews and questionnaires were used. Third,
by focusing the analyses on continuous cardiovascular
phenotypes, including both raw (e.g., coronary artery
calcium volume) and extracted latent traits, the power
to detect significant associations will be greater than
comparable analyses of dichotomized CAD traits (e.g.,
history of myocardial infarction). Fourth, the proposed
genetic investigations are designed to take advantage
of well-established genetic analytic tools supplemented
by novel analytic methods developed and validated by
the investigative team [103]. Fifth, multiple biomarkers and
other clinical data permit the examination of physiological
pathways by which depression affects CAD outcomes.
There is compelling evidence that autonomic dysregula-
tion is one of the mechanisms by which depression contrib-
utes to CAD [108]. Studies of depressed, medically-well
psychiatric patients have reported elevated levels of plasma
and urinary catecholamines (primarily norepinephrine)
compared to controls [109-115]. Studies have reported
higher heart rates and lower HRV in depressed patients
than in non-depressed controls, [111,113-120] consistent
with altered cardiac autonomic nervous system function
[90]. Abnormal HRV has been described as resulting from
an imbalance between the sympathetic and parasympa-
thetic regulatory control of the heartbeat [121] and/or
the lack of an integrated regulation of the heartbeat [122].
(Notably, low HRV also has predicted mortality in patients
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stable coronary disease [127] and abnormal heart rate tur-
bulence has been found to be a strong predictor of mortal-
ity after acute myocardial infarction as well [128-130]).
Biologic factors shared by both CAD and depression
suggest possible common genetic pathways, such as
inflammatory and/or serotonin-signaling pathways that
appear to underlie both diseases. Evidence of genetic plei-
otropy does not eliminate or fully explain other potential
causal relationships, including pathways by which certain
gene-environment interactions may cause depression
and depression may in turn accelerate the development,
progression, and/or morbidity associated with CAD [131].
For example, Nakatani et al. studied the “short” (S) allele of
the serotonin transporter gene-linked polymorphic region
(SLC6A4 5-HTTLPR, minor allele frequency 20%) in 2,509
Japanese post-myocardial infarction patients [132]. Depres-
sion was significantly more common among patients with
(48%) than without (35%) the S allele. The S allele predicted
an increased risk of cardiac events (hazards ratio = 1.69),
but its effect was reduced to non-significance by ad-
justment for depressive symptoms, suggesting that de-
pression may mediate the effect of this polymorphism
on cardiac outcomes.
Elevated inflammatory biomarkers, particularly CRP,
IL-6, and TNF-α, also have been found in medically
healthy adults with depression, and in depressed patients
with CAD [133-139]. These inflammatory molecules
are risk markers for cardiac morbidity and mortality
[57,58,63,65,66]. Thus, markers of proinflammatory and
serotonin signaling pathways that have been identified
as risk factors for CAD and cardiac events have also
been found to be elevated in depressed patients with
CAD. For this reason, genes involved in inflammatory and
serotonin-signaling pathways have recently been identified
as candidates for elucidating the mechanisms causing the
association between depression and CAD [72].
Limitations
Although the parent AAH project is a longitudinal study,
the AAH-Heart ancillary study is cross-sectional, and thus
causality cannot be determined. Second, although we can
estimate effects at the population level via the original
sample weights plus re-weighting adjustments based on
propensity scores for inclusion in AAH-Heart, this ap-
proach is somewhat less precise than estimates based on a
freshly-drawn population-based sample, albeit a great deal
less expensive than the latter method. Third, although we
examine a large number of biomarkers and clinical data, it
is impossible to include every potential mediating, moder-
ating, and/or confounding factor. Fourth, power predict-
ably will be adequate for many of the planned analysis but
marginal or low for others, depending on numerous issues
involved in the specific analytic approach being pursued.Summary
AAH-Heart provides an unparalleled opportunity to study
CAD-depression-gene relationships in a particularly vulner-
able population, i.e., AAs entering their senior years.
The investigations are designed to elucidate important
pathophysiological relationships and pathways to facilitate
identification of appropriate targets for clinical interven-
tions to modify the adverse bidirectional relationships be-
tween depression and CAD, not only in AA populations
but conceivably in other populations as well.
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